# A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

> **NCT05351047** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** AZD2373 subcutaneous injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05351047
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-04
- **Primary completion:** 2023-07-06
- **Final completion:** 2023-07-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05351047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05351047, "A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05351047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*